FDA grants accelerated approval for Jemperli to treat rectal cancer

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy drug Jemperli (dostarlimab-gxly) to treat specific adult patients with stage II or III rectal cancer. This regulatory decision provides a potential alternative to the standard clinical pathway of chemotherapy, radiation, and surgical intervention for patients whose tumors demonstrate specific genetic defects in DNA mismatch repair.

Key Clinical Takeaways:

• Jemperli targets rectal cancer patients with mismatch repair deficiency (dMMR), a condition where cells cannot effectively repair DNA replication errors, making the tumors more visible to the immune system.
• Clinical data indicates that approximately 75% of patients in the study group avoided surgery, chemotherapy, or radiation after a two-year follow-up period.
• The drug is administered intravenously every three weeks for up to six months, with ongoing monitoring required under the FDA’s accelerated approval program to confirm long-term efficacy and cancer recurrence rates.

Regulatory Approval of Dostarlimab for Rectal Cancer

The FDA granted approval for the use of Jemperli in patients previously untreated for rectal cancer. Standard protocols often involve neoadjuvant chemotherapy and radiation followed by surgery, which can lead to long-term impairment of bladder, bowel, and sexual function. In some clinical cases, patients undergo permanent colostomy, requiring an opening in the abdominal wall for waste diversion.

Jemperli Targets Tumors with Mismatch Repair Deficiency

The efficacy of Jemperli relies on the presence of mismatch repair deficiency (dMMR). In healthy cells, biological mechanisms repair minor errors that occur during DNA replication. In dMMR tumors, these repair systems are dysfunctional, leading to an accumulation of mutations. This genetic instability makes the malignant cells more easily detectable and targetable by the patient’s own immune system.

The FDA approval is limited to patients with stage II or III rectal cancer where the disease has spread to adjacent tissues or lymph nodes but has not metastasized to distant organs. Confirmation of dMMR status via laboratory testing is a mandatory prerequisite for prescription. This specific genetic profile is present in only a small percentage of total rectal cancer cases.

Most Trial Participants Avoid Surgery and Chemotherapy

The regulatory decision was based on preliminary results from a clinical trial involving 154 patients. Participants received Jemperli intravenously once every three weeks for a duration of six months, totaling a maximum of nine doses. Data presented by the FDA indicates that after a follow-up period exceeding two years, three out of every four participants remained free from the need for surgery, radiation, or chemotherapy.

Historical data from a separate study conducted at Memorial Sloan Kettering Cancer Center involved 50 patients treated with the same immunotherapy. Following the completion of the treatment course, researchers observed no clinical signs of cancer in any of the participants. Among a subset of 27 patients monitored for at least three years, only one individual experienced a recurrence of the disease.

GSK Must Verify Long-Term Clinical Benefit

Because the FDA granted this approval under the “accelerated approval” program, the manufacturer, GSK, is required to conduct ongoing surveillance to verify clinical benefit. Tony Wood, scientific director at GSK, characterized the approval as an advancement toward personalized care for this patient population. The long-term durability of the response remains an area of active investigation, as the exact probability of cancer recurrence over extended periods is not yet fully defined.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

More on this story: EMA recommends daraxonrasib for metastatic pancreatic cancer · Researchers: Predictive Biomarkers Central to Refining Colon Cancer Immunotherapy